The Natural Progressive History of T2DM. | |
---|---|
I. | LATENT STAGE: [EARLY] |
 | Insulin Resistance: |
 |    Genetic Component |
 |    Environmental component. Modifiable: obesity/sedentary life style. Nonmodifiable: aging |
 | Beta Cell Defect: (Dysfunction) |
 |    Genetic ....... Abnormal processing, storage or secretion. |
 |    Intracellular/extracellular oligomers of Islet Amyloid toxicity to the Beta Cell. Abnormal processing, storage or secretion |
 | Islet Amyloid: Diffusion Barrier: Secretory Defect: Intra Islet Absorptive Defect: |
II. | TRANSITION STAGE: [MIDDLE] |
 | Persistent Hyperinsulinemia, Hyperproinsulinemia. → Ang II Accelerated Atherosclerosis |
 | Persistent Hyperamylanemia. → AngII Accelerated Atherosclerosis |
 | Continued remodeling of the endocrine pancreas (amyloid). |
 | Beta cell displacement, dysfunction, mass reduction due to the toxic effect of IAPP oligomers and the progressive developing diffusion barrier. |
III. | IGT STAGE (Impaired Glucose Tolerance): [LATE]"Pre-diabetes" Human Health Services (HHS) and American Diabetes Association (ADA) term. |
 | [Start treatment at this time] |
 | Diagnose earlier: rejuvenation of the 2 hour glucose tolerance blood sugar 140–199 mg/dl |
 | Increased insulin resistance [Feeds forward] > Glucotoxicity [Feeds forward] > Insulin resistance [Feeds forward] > Glucotoxicity: creating a vicious cycle. |
 | Islet amyloid. Increasing beta cell defect. Loss of beta cell mass with displacement. (Remodeling of islet architecture including extracellular matrix). Beta cell loss centrally. |
IV. | IFG STAGE (Impaired Fasting Glucose): [LATER]"Pre-diabetes" Human Health Services (HHS) and American Diabetes Association (ADA) term. |
 |    Blood sugar ranging [110–125 mg/dL] |
 |    *ADA new cut point IFG Nov 2003: [100–125 mg/dl] |
 | Impaired hepatic glucose production: Increasing global insulin resistance (hepatic) with subsequent gluconeogenesis. Feeding forward in the vicious cycle to accelerate insulin resistance globally. |
V. | OVERT STAGE: [TOO LATE] FBG 126 or greater: Random or 2 hour OGTT 200 or > |
 | [50% loss of beta cell function at the time of clinical diagnosis] |
 | Use medications that do not increase endogenous insulin or amylin. Use combination therapy. Start treatment at stage III-IV (IGT-IFG). |
. | Paradigm Shift. → Diagnose Early → Start treatment Early → Stage III: IGT. |